证券代码：688133 证券简称：泰坦科技 公告编号：2025-036 上海泰坦科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 84 | | --- | --- | | 普通股股东人数 | 84 | | 2、出席会议的股东所持有的表决权数量 | 51,900,777 | | 普通股股东所持有表决权数量 | 51,900,777 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 31.5627 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 31.5627 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 1、表决方式 （一） 股东大会召开的时间：2025 年 9 月 5 日 （二） ...

德恒上海律师事务所 关于 上海泰坦科技股份有限公司 2025年第一次临时股东大会会议的 法律意见 澳恆上海津師事務所 DEHENG SHANGHAI LAW OFFICE 上海市虹口区东大名路 501 号上海白玉兰广场办公楼 23 层 电话：021-5598 9888 传真：021-5598 9898 邮编：200080 德恒上海律师事务所 关于上海泰坦科技股份有限公司 2025 年第一次临时股东大会的法律意见 德恒上海律师事务所 关于 上海泰坦科技股份有限公司 2025年第一次临时股东大会会议的 法律意见 德恒 02G20240317-00002 号 致:上海泰坦科技股份有限公司 德恒上海律师事务所(以下简称"本所")受上海泰坦科技股份有限公司 (以 下简称"泰坦科技"或者"公司"）的委托,指派本所承办律师列席公司于 2025 年 9 月 5 日 (星期五）下午 14:30 在上海市徐汇区石龙路 89 号召开的 2025 年第 一次临时股东大会会议（以下简称"本次股东大会"），就本次股东大会召开的 合法性进行见证并出具本法律意见。 本所承办律师依据本法律意见出具目前已经发生或存在的事实和《中华人民 共和国公 ...

Group 1 - Titan Technology's stock price has declined for eight consecutive days, with a total drop of 19.16%, currently trading at 24.38 CNY per share and a market capitalization of 4.009 billion CNY [1] - The company, established in October 2007 and listed in October 2020, provides integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, and specialized chemicals [1] - The revenue composition of Titan Technology includes 25.08% from proprietary specialty chemicals, 20.48% from proprietary high-end reagents, and 15.65% from third-party research instruments and consumables [1] Group 2 - Rongtong Fund holds 1.161 million shares of Titan Technology in its Rongtong Healthcare Industry Mixed Fund A/B, representing 3.28% of the fund's net value, making it the ninth largest holding [2] - During the eight-day decline, the fund has incurred a floating loss of approximately 670.98 thousand CNY [2] - The Rongtong Healthcare Industry Mixed Fund A/B has achieved a year-to-date return of 22.05% and a one-year return of 33.89% [2] Group 3 - The fund managers of Rongtong Healthcare Industry Mixed Fund A/B are Wan Minyuan and Liu Xiyang, with Wan having a tenure of nearly 10 years and a best fund return of 157.54% during his management [3] - Liu Xiyang has been managing the fund for about 1.5 years, with a best fund return of 4.17% during his tenure [3]

Core Viewpoint - Titan Technology reported a decline in total revenue for the first half of 2025, while achieving significant growth in net profit due to strategic adjustments in its business operations [1] Financial Performance - Total revenue for the first half of 2025 was 1.219 billion yuan, a year-on-year decrease of 12.7% [1] - Net profit attributable to shareholders was 9.7652 million yuan, reflecting a year-on-year increase of 91.55% [1] - The diluted earnings per share were not specified, but the significant increase in net profit indicates improved profitability [1] Strategic Adjustments - The decline in revenue was primarily due to the company's decision to adjust its business strategy, which involved relinquishing certain unprofitable or capital-intensive operations [1] - The management emphasized a transformation in the business model, gradually shifting focus towards higher-margin operations [1] Operational Improvements - During the reporting period, the company made notable advancements in production capacity, optimization of the sales team, and new product research and market promotion [1]

Group 1 - Feng Liu's Gao Yi Lin Shan No.1 Fund entered the top ten circulating shareholders of 12 A-shares with a total holding value of approximately 15.445 billion [1] - The fund increased its positions in Angel Yeast, Songjing Co., and Tongrentang, while reducing holdings in Hikvision, Ruifeng New Materials, Zhongju High-tech, Guoci Materials, Dongcheng Pharmaceutical, and Titan Technology [1][5] - Deng Xiaofeng's Gao Yi Xiaofeng No.2 Fund entered the top ten circulating shareholders of 5 A-shares with a total holding value of approximately 6.768 billion, while the Xiaofeng Hongyuan Trust Plan entered 2 A-shares with a total holding value of approximately 3.754 billion [9] Group 2 - Feng Liu's investment philosophy includes three types: investing in well-known good companies, lesser-known good companies, and unknown good companies, each with varying levels of risk and return [6][7] - Deng Xiaofeng emphasizes assessing a company's capacity and space, profit margin based on business characteristics, and the importance of forward-looking investment strategies in rapidly changing industries [18] - The current market trend shows a migration of funds from low-yield deposits to capital markets, driven by the pursuit of higher potential returns [25][27]

Market Overview - The Shanghai Composite Index closed at 3875.53 points, with a change of 0.46% [1] - The total trading volume of A-shares reached 27,776.47 billion yuan [1] Technical Analysis - A total of 63 A-shares experienced a "death cross" where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Haitai Biological: 5-day MA at 50.56 yuan, 10-day MA at 51.97 yuan, a difference of -2.72% [1] - Titan Technology: 5-day MA at 27.25 yuan, 10-day MA at 27.85 yuan, a difference of -2.16% [1] - Anglikang: 5-day MA at 50.17 yuan, 10-day MA at 51.27 yuan, a difference of -2.15% [1] Individual Stock Performance - Haitai Biological: Today's change of -2.67%, with a turnover rate of 8.82% [1] - Titan Technology: Today's change of -2.29%, with a turnover rate of 4.22% [1] - Anglikang: Today's change of -0.85%, with a turnover rate of 6.98% [1] - Other stocks with notable performance include: - Rainbow Group: Today's change of -0.13%, with a turnover rate of 3.47% [1] - Wanli Stone: Today's change of -0.51%, with a turnover rate of 2.18% [1] Additional Observations - The market shows a trend of declining stock prices for several companies, indicating potential bearish sentiment [1][2] - The analysis of moving averages suggests a cautious approach for investors focusing on these stocks [1][2]

Market Overview - The Shanghai Composite Index is at 3864.71 points with a change of 0.18% [1] - The total trading volume of A-shares is 138.21 billion yuan [1] Technical Analysis - 62 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Haitai Biological: 5-day MA is -2.28% below the 10-day MA [1] - Titan Technology: 5-day MA is -2.07% below the 10-day MA [1] - Anglikang: 5-day MA is -1.88% below the 10-day MA [1] Individual Stock Performance - Haitai Biological (300683): Today's change is +1.95%, with a 5-day MA of 51.01 yuan and a 10-day MA of 52.20 yuan [1] - Titan Technology (688133): Today's change is -1.41%, with a 5-day MA of 27.30 yuan and a 10-day MA of 27.88 yuan [1] - Anglikang (002940): Today's change is +1.84%, with a 5-day MA of 50.44 yuan and a 10-day MA of 51.40 yuan [1] - Other stocks with notable performance include: - Rainbow Group (300314): +0.04% change, 5-day MA of 23.44 yuan [1] - Wanli Stone (002785): -0.89% change, 5-day MA of 29.62 yuan [1] Summary of Stocks with Death Cross - A list of stocks experiencing a death cross includes: - Haitai Biological, Titan Technology, Anglikang, and others with varying degrees of percentage differences between their moving averages [1][2]

Summary of Key Points Core Viewpoint - The company plans to continue using part of the idle raised funds for cash management, ensuring that it does not affect the investment projects and the safety of the raised funds, while aiming to increase returns for the company and its shareholders [1][4][6]. Fundraising Basic Situation - The company raised a total of RMB 1,003,512,562.56 from the issuance of 7,624,896 A shares at a price of RMB 131.61 per share, with a net amount of RMB 985,184,001.46 after deducting related issuance costs [1]. Previous Use of Idle Funds - The company approved the use of up to RMB 400 million of idle funds for cash management, focusing on high-security and liquid investment products, with a rolling usage period of 12 months [2][3]. Current Cash Management Plan - The company intends to use up to RMB 400 million of idle funds for cash management, with a focus on safe and liquid investment products, maintaining the same 12-month usage period [3][4]. Investment Purpose - The goal is to improve the efficiency of fund usage and increase returns for the company and shareholders without affecting the investment projects [3][4]. Investment Products - The company will invest in high-security and liquid products such as agreement deposits, structured deposits, time deposits, notice deposits, and large certificates of deposit, ensuring these funds are not used for pledging or securities investment [3][4][7]. Decision Validity Period - The decision is valid for 12 months from the date of board approval [3][4]. Authorization Matters - The board authorizes the management to make investment decisions and sign relevant documents within the approved limits and validity period [4][6]. Information Disclosure - The company will comply with relevant regulations for timely information disclosure and will not change the purpose of the raised funds [4][8]. Cash Management Income Distribution - Income from cash management will be used to supplement investment project funding and daily operational liquidity, with funds returned to the special account upon maturity [4][6]. Impact on the Company - The cash management plan will not affect the normal operation of the company or the investment projects, and it aims to generate additional returns for the company and shareholders [4][6][7]. Independent Director and Supervisory Board Opinions - Both the independent directors and the supervisory board agree that the cash management plan is compliant with regulations and beneficial for the company and shareholders, ensuring no harm to the interests of minority shareholders [6][7][8].

Group 1 - The core viewpoint of the announcement is that the Supervisory Board of Titan Technology has approved the 2025 semi-annual report and confirmed its compliance with relevant laws and regulations [1][2][3] - The meeting of the Supervisory Board was held on August 27, 2025, with all three supervisors present, ensuring the legality and validity of the resolutions made [1] - The Supervisory Board unanimously agreed that the semi-annual report accurately reflects the company's financial status and operational results for the first half of 2025 [2][3] Group 2 - The Supervisory Board confirmed that the management of raised funds complies with the relevant regulations and that there are no violations in the use of these funds [2][3] - The company plans to continue using up to RMB 400 million of idle funds from the 2021 A-share issuance for cash management in safe and liquid investment products, ensuring that this does not affect the ongoing investment projects [3][4] - The resolution regarding the use of idle funds was also unanimously approved by the Supervisory Board [4][5]

Core Viewpoint - Shanghai Titan Technology Co., Ltd. is convening its first extraordinary general meeting of shareholders in 2025 to discuss the proposal for the registration and issuance of short-term financing bonds, aimed at optimizing its debt structure and reducing financial costs [5][10]. Meeting Procedures - The meeting will take place on September 5, 2025, at 14:30, in Shanghai, with both on-site and online voting options available [6]. - Shareholders or their representatives must arrive 30 minutes prior to the meeting for registration and must present necessary identification documents [2]. - The meeting will follow a structured agenda, including the announcement of attendees, discussion of proposals, and voting on resolutions [7]. Proposal for Short-term Financing Bonds - The company plans to apply for the registration of short-term financing bonds not exceeding RMB 100 million, with a registration validity of two years [8]. - The funds raised will be used for repaying interest-bearing debts, project construction, and supplementing working capital [8]. - The board of directors seeks authorization from the shareholders to manage the issuance process, including determining the timing, scale, and use of funds [9]. Impact and Approval Process - The issuance of these bonds is expected to enhance the company's financial flexibility and support its operational needs without significantly impacting its normal business operations [10]. - The proposal has already been approved by the company's board and supervisory board and requires shareholder approval and registration with the China Interbank Market Dealers Association to proceed [10].